Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$182.50
$182.82
$99.91
$187.45
$40.34B1.253.31 million shs10 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.40
-2.1%
$21.04
$17.24
$28.56
$13.73B0.941.25 million shs1.25 million shs
Shiseido Co. stock logo
SSDOY
Shiseido
$17.88
+3.2%
$16.90
$15.32
$32.17
$7.15B0.3735,200 shs11,083 shs
UCB SA stock logo
UCBJF
UCB
$203.85
$184.12
$149.85
$209.66
$34.78B0.47517 shs221 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+4.85%-7.32%+13.77%-16.76%
Shiseido Co. stock logo
SSDOY
Shiseido
0.00%-7.31%+4.23%+2.88%-36.57%
UCB SA stock logo
UCBJF
UCB
0.00%+2.01%+6.23%+35.27%+54.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
1.3355 of 5 stars
0.00.00.03.80.61.71.9
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
4.0955 of 5 stars
3.35.00.00.03.40.03.1
Shiseido Co. stock logo
SSDOY
Shiseido
1.3191 of 5 stars
0.03.00.80.02.10.01.9
UCB SA stock logo
UCBJF
UCB
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.00
N/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.67
Moderate Buy$37.8076.64% Upside
Shiseido Co. stock logo
SSDOY
Shiseido
0.00
N/AN/AN/A
UCB SA stock logo
UCBJF
UCB
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest SSDOY, ALXN, GMAB, and UCBJF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
6/23/2025
UCB SA stock logo
UCBJF
UCB
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOverweight
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$6.07B6.65$22.81 per share8.00$53.24 per share3.43
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.40$1.52 per share14.11$8.04 per share2.66
Shiseido Co. stock logo
SSDOY
Shiseido
$6.55B1.09$1.03 per share17.39$10.44 per share1.71
UCB SA stock logo
UCBJF
UCB
$5.27B7.32$8.76 per share23.28$50.52 per share4.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$603.40M$11.6059.6413.150.9310.89%23.43%15.06%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.1612.026.5135.11%18.08%14.52%8/14/2025 (Estimated)
Shiseido Co. stock logo
SSDOY
Shiseido
-$68.94M-$0.07N/A21.54N/A-0.40%-0.61%-0.30%8/6/2025 (Estimated)
UCB SA stock logo
UCBJF
UCB
$371.23MN/A0.0028.87N/AN/AN/AN/A7/23/2025 (Estimated)

Latest SSDOY, ALXN, GMAB, and UCBJF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Shiseido Co. stock logo
SSDOY
Shiseido
$0.0569$0.06+$0.0031$0.06$1.72 billion$1.54 billion
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Shiseido Co. stock logo
SSDOY
Shiseido
$0.070.39%N/AN/A N/A
UCB SA stock logo
UCBJF
UCB
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.19
4.52
3.96
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32
Shiseido Co. stock logo
SSDOY
Shiseido
0.36
1.20
0.79
UCB SA stock logo
UCBJF
UCB
0.33
1.19
0.78

Institutional Ownership

CompanyInstitutional Ownership
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
82.94%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Shiseido Co. stock logo
SSDOY
Shiseido
0.02%
UCB SA stock logo
UCBJF
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
4.03%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Shiseido Co. stock logo
SSDOY
Shiseido
N/A
UCB SA stock logo
UCBJF
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
3,837221.02 millionN/AOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.66 millionOptionable
Shiseido Co. stock logo
SSDOY
Shiseido
27,908399.66 millionN/ANot Optionable
UCB SA stock logo
UCBJF
UCB
9,083189.02 millionN/ANot Optionable

Recent News About These Companies

UCB (OTCMKTS:UCBJF) Shares Gap Down - Here's Why
UCB price target raised to EUR 220 from EUR 130 at Berenberg
UCB price target raised to EUR 200 from EUR 105 at Morgan Stanley
UCB assumed with an Equal Weight at Morgan Stanley
UCB SA (0NZT) Receives a Hold from Kepler Capital
UCB SA (0NZT) Gets a Buy from Barclays
UCB SA (0NZT) Receives a Buy from Barclays
UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank
UBS Remains a Buy on UCB SA (0NZT)
Artisan Global Equity Fund Q3 2024 Commentary
Artisan International Fund Q3 2024 Commentary
Barclays Keeps Their Buy Rating on UCB SA (0NZT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alexion Pharmaceuticals stock logo

Alexion Pharmaceuticals NASDAQ:ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.40 -0.46 (-2.10%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$21.44 +0.04 (+0.19%)
As of 07/11/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Shiseido stock logo

Shiseido OTCMKTS:SSDOY

$17.88 +0.56 (+3.23%)
As of 07/11/2025 03:58 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

UCB stock logo

UCB OTCMKTS:UCBJF

$203.85 0.00 (0.00%)
As of 07/11/2025 03:35 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.